

Haesuk Park, Ph.D, MPharm

Curriculum Vitae

Office Address

University of Florida
College of Pharmacy
Department of Pharmaceutical Outcomes & Policy
Malachowsky Hall #6020
1889 Museum Rd. Suite 6300
P.O. Box 100496
Gainesville, FL 32611
(352) 273-6261 (office)
(352) 273-6270 (fax)
Email: hpark@cop.ufl.edu

EDUCATION

Fall 2008 – May 2013	The University of Texas at Austin , Austin, Texas Doctor of Philosophy, Pharmacy
Sep 2000 – Aug 2002	Chung-Ang University , Seoul, South Korea Master of Pharmacy, Pharmaceutics
Sep 1996 – Aug 2000	Chung-Ang University , Seoul, South Korea Bachelor of Pharmacy

EMPLOYMENT

Jul 2019 – Present	University of Florida College of Pharmacy , Gainesville, Florida Associate Professor (tenured)
Aug 2013 – Jun 2019	University of Florida College of Pharmacy , Gainesville, Florida Assistant Professor
Sep 2009 – May 2013	The University of Texas at Austin College of Pharmacy , Austin, Texas Graduate Research Assistant
Jun 2011 – Aug 2011	Shire Pharmaceuticals , Wayne, Pennsylvania Summer Internship
Jun 2010 – Aug 2010	Xcenda , Palm Harbor, Florida Summer Internship

AFFILIATIONS

2019 – Present	Member, Center for Drug Evaluation and Safety (CoDES), College of Pharmacy, University of Florida
2019 – Present	UF core faculty, The Southern HIV and Alcohol Research Consortium (SHARC), University of Florida

GRANTS (reverse chronological order)

Current Funding

Title: "Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool"

Funding Source: NIH/NIDA R01 (R01DA050676)

Role: PI

Total costs: \$3,237,039

Time period: September 2023 – June 2028

Title: "Cardiovascular Outcomes in Patients with Narcolepsy"

Funding Source: Sleep Research Society Foundation Focused Research Award (23-FRA-001)

Role: Co-I (PI: Dr. Kaufmann)

Total costs: \$392,868

Time period: July 2022 – June 2023

Title: "Sparkling Advancements in Genomic Medicine- A depression and opioid pragmatic trial in pharmacogenetics (ADOPT PGx)"

Funding Source: NIH/National Human Genome Research Institute

Role: Co-I (PI: Dr. Johnson)

Total costs: \$9,818,662

Time period: July 2018 – June 2026

Title: "Improving medication adherence with telehealthcare MTM to change health outcomes in adolescents and young adults with asthma"

Funding Source: NIH/NHLBI R01 (1 R01 HL136945)

Role: UF PI/PD (12%) – subaward with Nemours Children's Hospital (PI: Dr. Blake)

UF total costs: \$714,513

Time period: May 2018 – July 2025

Title: "A behavioral economic intervention to reduce marijuana use in truant youth"

Funding: NIH/NIDA K23 (K23DA046565)

Total costs: \$843,994 (in kind)

Role: Co-mentor (PI: Dr. Yurasek)

Time period: April 2019-March 2024

Completed Grants

Title: "Trajectories of apixaban for extended treatment of recurrent venous thromboembolism: a retrospective cohort study"

Funding Source: American Thrombosis Investigator Initiated Research Program (ARISTA)

Role: Principal investigator (20%)

Total costs: \$800,000

Time period: June 2020 – April 2023

Title: "Medicaid prior authorization policies for chronic hepatitis C treatment in vulnerable populations"

Funding Source: NIH/NIDA K01 (K01DA045618)

Total costs: \$648,422

Role: Principal investigator (75%)

Time period: May 2018 – April 2023

Title: "Identifying and characterize PrEP users from OneFlorida electronic health records and explore provider's insights on a PrEP related clinical decision support tool"

Funding Source: UF CTSI Precision Medicine

Total costs: \$30,525

Role: Co-I

Time period: July 2021 – June 2022

Title: "Using machine learning to predict direct-acting antiviral treatment failure in patients with chronic hepatitis C virus infection"

Funding Source: UF Informatics Institute and UF CTSI

Role: Principal investigator (5%)

Total costs: \$60,000

Time period: April 2019 – March 2020

Title: "Medicaid prior authorization policies for chronic hepatitis C treatment in vulnerable populations; A pilot study"

Funding Source: UF College of Pharmacy PROSPER Research Enhancement Award

Total costs: \$39,875 (5%)

Role: Principal investigator

Time period: January 2018 – April 2019

Title: "Clinical and Health Economic Outcomes of a Digital Health Offering in a Patient Population with Cardiovascular and Metabolic Chronic Diseases"

Funding Source: Proteus Digital Health

Total costs: \$68,625 (20%)

Role: Principal investigator

Time period: January 2017 – June 2018

Title: "Effects of Medicare Dialysis Quality Incentive Program on Anemia Care"

Funding source: UF College of Pharmacy PROSPER Research Enhancement Award

Role: Principal investigator (5%)

Total costs: \$33,275

Time period: August 2016 – July 2017

Title: "Quality-adjusted cost of care associated with evolution of treatment for chronic hepatitis C"

Funding source: Gilead Sciences, Inc

Role: Principal investigator

Total costs: \$118,863 (35%)

Time period: April 2015 – December 2016

Title: "A meta-analytic estimation of the burden of extra hepatic manifestations of HCV"

Funding source: Gilead Sciences, Inc

Role: Principal investigator

Total costs: \$112,437 (30%)

Time period: September 2014 – December 2015

Title: "Impact of a telephonic outreach program on medication adherence in Medicare beneficiaries"

Funding source: Florida Department of Health

Role: Co-PI (Research PI)

Total costs: \$92,623 (24%)
Time period: September 2014 – July 2015

Title: “Cost-effectiveness Model of Sofosbuvir/ledipasvir for Hepatitis C virus infection”
Funding source: Gilead Sciences, Inc
Role: Principal investigator
Total costs: \$89,950 (40%)
Time period: June 2014 – August 2015

Title: “Cost-effectiveness Model of Sofosbuvir plus peginterferon/ribavirin for Hepatitis C virus infection”
Funding source: Gilead Sciences, Inc
Role: Principal investigator
Total costs: \$89,950 (55%)
Time period: November 2013 – August 2014

Primary Mentor for Student Fellowship

Ghadeer Dawwas, MS, 2017-2018, American Association of University Women (AAUW)
International Doctoral Degree Fellowship, \$20,000.

PUBLICATIONS (Peer reviewed original research)

Total number of original peer-reviewed articles: 105

Total number of corresponding/senior author publications: 57; Total number of first author: 23

Underline denotes corresponding author; g denotes graduate student; p denotes postdoc fellow.

1. Unigwe I (g)*, Goodin A, Lo-Ciganic W, Cook R, **Park H**. Trajectories of pre-exposure prophylaxis (PrEP) adherence among commercially insured individuals. *Clinical Infectious Diseases* 2023. Published online December 8, 2023. Doi:10.1093/cid/ciad756. (Impact factor: 21; Cited by 1; Altmetric score: 3).
2. Desai R* (g), Smith S, Mohandas R, Brown J, **Park H**. Risk of fractures with concomitant use of calcium channel blockers and selective serotonin reuptake inhibitors. *Annals of Pharmacotherapy* 2023 Dec;11:10600280231218286. doi: 10.1177/10600280231218286. Epub ahead of print. PMID: 38078408. (Impact factor: 2.9; Cited by N/A; Altmetric score: 2).
3. Riaz M (g)*, Smith S, Dietrich E, Winchester D, Guo J, **Park H**. Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in heart failure with preserved ejection fraction: A cohort study. *American Journal of Health-System Pharmacy* . (Impact factor: 1.9; Cited by N/A; Altmetric score: N/A). [accepted]
4. Chang C (g), Jones B, Hincapie-Castillo J, **Park H**, Heldermon C, Diaby V, Wilson D, Lo-Ciganic W. The association between trajectories of prescription opioid use and the risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors. *Breast Cancer Research and Treatment* 2024 Jan 8. doi: 10.1007/s10549-023-07205-6. Epub ahead of print. PMID: 38191684. (Impact factor: 3.8; Cited by N/A; Altmetric score: N/A).
5. Liu Y, Siddiqi K, Cho H, **Park H**, Prosperi M, Cook B. Demographics, trends, and clinical characteristics of HIV pre-exposure prophylaxis (PrEP) recipients and people newly diagnosed with HIV from large electronic health records in Florida. *AIDS Patient Care*

- and STDs 2024 Jan;38(1):14-22. doi: 10.1089/apc.2023.0220. PMID: 38227279; PMCID: PMC10794838. (Impact factor: 3.76; Cited by N/A; Altmetric score: 1).
6. Kang HR*^(p), Jones BL, Lo-Ciganic WH, DeRemer CE, Dietrich EA, Huang PL, Wilson DL, **Park H**. Trajectories of Adherence to Extended Treatment with Direct Oral Anticoagulants and Risks of Recurrent Venous Thromboembolism and Major Bleeding. *Journal of Managed Care & Specialty Pharmacy* 2023; 29(11):1219-1230. <https://doi.org/10.18553/jmcp.2023.29.11.1219>. (Impact factor: 2.338; Cited by N/A; Altmetric score: N/A).
 7. Hernandez-Con P* (g), Wilson DL, Tang H, Unigwe I, Riaz M, Ourhaan N, Jiang X, Song HJ, Joseph A, Henry L, Cook R, Jayaweera D, **Park H**. The cascade of hepatitis C virus infection in the direct-acting antiviral era: a systematic review and meta-analysis. *American Journal of Preventive Medicine* 2023 Jun 26:S0749-3797(23)00278-7. doi: 10.1016/j.amepre.2023.06.016. Epub ahead of print. PMID: 37380088. (Impact factor: 4.15; Cited by 1; Altmetric score: 3).
 8. Unigwe I* (g), Cook R, Janelle J, **Park H**. Trends in recommended Screening and monitoring tests for users of HIV pre-exposure prophylaxis before and during the COVID-19 Pandemic, 2016-2020. *American Journal of Preventive Medicine FOCUS* 2023 Jul 30;2(4):100134. doi: 10.1016/j.focus.2023.100134. PMID: 37790950; PMCID: PMC10546544. (Impact factor: 6.6; Cited by N/A; Altmetric score: 2).
 9. Jiang X* (g), Song H (p), Wilson D, Chang C, Lo-Ciganic W, **Park H**. Impact of direct-acting antivirals on incidence of hepatocellular carcinoma and mortality among Medicaid beneficiaries with Hepatitis C. *Medical Care* 2023;61(8):505-513. doi: 10.1097/MLR.0000000000001870. PMID: 37223993. (Impact factor: 3.178; Cited by N/A; Altmetric score: 2).
 10. Wang W* (g), Chen C, Lo Re II V, Chang S, Wilson D, **Park H**. Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the U.S. *Pharmacoepidemiology and Drug Safety* 2023 Jun 6. doi: 10.1002/pds.5651. Epub ahead of print. PMID: 37278688. (Impact factor: 2.732; Cited by N/A; Altmetric score: 2).
 11. Riaz M* (g), Smith S, Dietrich E, Winchster D, Guo J, **Park H**. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction. *Pharmacotherapy* 2023 Oct;43(10):1024-1031. doi: 10.1002/phar.2853. Epub 2023 Jul 23. PMID: 37459069. (Impact factor: 4.1; Cited by N/A; Altmetric score: 19).
 12. Wang H (g), Svensson M, Shao H, Vouri S, **Park H**. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia. *Journal of Managed Care & Specialty Pharmacy* 2023;29(8): 884-895. doi: 10.18553/jmcp.2023.29.8.884. PMID: 37523313; PMCID: PMC10397333. (Impact factor: 2.338; Cited by 1; Altmetric score: 1).
 13. Garg M* (g), Venugopalan V, Vouri S, Diaby V, Lovine N, **Park H**. Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population-based propensity score-matched cohort study. *Pharmacotherapy* Sep;43(9):883-893. doi:

- 10.1002/phar.2841. Epub 2023 Jul 11. PMID: 37381584. (Impact factor: 4.1; Cited by 1; Altmetric score: 75).
14. Kang H* (p), Hernandez-Con P (g), Heo J, Wilson DL, Blake K, Lang J, **Park H**. Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States. *Journal of Managed Care & Specialty Pharmacy* 2023 Jul;29(7):721-731. doi: 10.18553/jmcp.2023.29.7.721. PMID: 37404074. (Impact factor: 2.338; Cited by N/A; Altmetric score: N/A).
15. Kang H* (p), Jones B, Lo-Ciganic, DeRemer C, Dietrich E, Huang P, **Park H**. Trajectories of adherence to extended treatment with warfarin and risks for recurrent venous thromboembolism and major bleeding. *Research and Practice in Thrombosis and Haemostasis* 2023 Mar 27;7(3):100131. doi: 10.1016/j.rpth.2023.100131. PMID: 37159747; PMCID: PMC10163671. (Impact factor: 4.6; Cited by N/A; Altmetric score: N/A).
16. Kang H* (p), Dietrich E, Huang P, Lo-Ciganic, DeRemer C, **Park H**. Comparative effectiveness and safety of direct oral anticoagulants among patients with recurrent venous thromboembolism. *Clinical and Translational Science* 2023 Jun;16(6):946-954. doi: 10.1111/cts.13510. Epub 2023 Mar 23. PMID: 36891985; PMCID: PMC10264957. (Impact factor: 4.689; Cited by N/A; Altmetric score: N/A).
17. **Park H**, Kang H, Huang P, Dietrich, Deremer, Lo-Ciganic. Trajectories of oral anticoagulation adherence and clinical outcomes during long-term anticoagulation among Medicare beneficiaries newly diagnosed with venous thromboembolism. *Annals of Pharmacotherapy* 2023 Dec;57(12):1349-1360. doi: 10.1177/10600280231155489. Epub 2023 Mar 31. PMID: 36999519. (Impact factor: 3.46; Cited by N/A; Altmetric score: 2).
18. Riaz M* (g), Smith S, Dietrich E, Winchester D, Guo J, **Park H**. Trends in pharmacotherapy utilization among patients with heart failure with preserved ejection fraction. *American Heart Journal Plus: Cardiology Research and Practice* 2023;26:100259. <https://doi.org/10.1016/j.ahjo.2023.100259>. (Impact factor: 0.6; Cited by N/A; Altmetric score: 2).
19. Chang C (g), **Park H**, Hincapie-Castillo J, Heldermon C, Diaby V, Yang S (g), Wilson D, Lo-Ciganic W. Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression. *Journal of Managed Care & Specialty Pharmacy* 2023 Apr;29(4):431-445. doi: 10.18553/jmcp.2023.29.4.431. PMID: 36989452. (Impact factor: 2.338; Cited by N/A; Altmetric score: 1).
20. **Park H**, Brown C, Wilson DL, Huang PL, Hernandez-Con P, Horne P, Goodin A, Joseph A, Segal R, Cabrera R, Cook RL. Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States. *Prev Med Rep.* 2023 Feb 13;32:102138. doi: 10.1016/j.pmedr.2023.102138. PMID: 36865395; PMCID: PMC9971512. (Impact factor: 2.66; Cited by N/A; Altmetric score: 3).
21. **Park H**, Lo-Ciganic W, Huang J, Wu Y, Henry L, Peter J, Sulkowski M, Nelson. Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. *Scientific Reports* 2022 Oct

- 27;12(1):18094. doi: 10.1038/s41598-022-22819-4. PMID: 36302828; PMCID: PMC9613877. (Impact factor: 4.996; Cited by N/A; Altmetric score: 1).
22. **Park H**, Kang H, Huang P, Lo-Ciganic W, DeRemer C, Wilson DL, Dietrich E. Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism. *Clinical and Translational Science* 2023;16(1):128-139. Doi: 10.1111/cts. 10.1111/cts.13433. Epub. PMID:36200137; PMCID: PMC9841301. (Impact factor: 4.689; Cited by N/A; Altmetric score: 1)
23. Jiang X* (g), Song H (p), Chang CY (g), Wilson D, Lo-Ciganic W, **Park H**. Disparities in access to hepatitis C treatment among Arizona Medicaid beneficiaries with chronic hepatitis C. *Medical Care* 2023;61(2):81-86. DOI: 10.1097/MLR.0000000000001801 PMID: 36453625; PMCID: PMC9839474. (Impact factor: 3.081; Cited by 1; Altmetric score: 4)
24. Jiang X* (g), Diaby V, Lo-Ciganic W, Martin S, Parker R, Wang W, **Park H**. Economic impact of universal Hepatitis C virus testing for middle aged adults who inject drugs. *American Journal of Preventive Medicine* 2022; Oct 15;S0749-3797(22/)00448-2. doi:10.1016/j.amepre.2022.08.016. PMID: 36257884. PMCID: [PMC10074824](#). (Impact factor: 5.5; Cited by N/A; Altmetric score: 3).
25. Wang C (g), Vouri S, **Park H**. Heldermon C, Brown J. Comparative effectiveness of pegfilgrastim biosimilars versus originator for prevention of febrile neutropenia: a retrospective cohort study. *Journal of Managed Care & Specialty Pharmacy* 2023 Feb;29(2):119-127. doi: 10.18553/jmcp.2023.29.2.119. PMID: 36705287; PMCID: PMC10387906. (Impact factor: 2.73; Cited by N/A; Altmetric score: 1).
26. Alawan A.A.(g), Friedman J, **Park H**, Segal R, Brumback B, Hartzema A. Comparative Safety of Sleeve Gastrectomy and Roux-en-Y: A Propensity Score Analysis. *World J Surg.* 2022 July 15. doi: 10.1007/s00268-022-06664-0. (Impact factor: 3.35; Cited by N/A; Altmetric score: N/A).
27. **Park H**, Desai R*(g), Liu X (p), Smith SM, Hincapie-Castillo J, Henry L, Goodin A, Gopal S, Pepine CJ, Mohandas R. Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis. *Clinical Journal of the American Society of Nephrology (CJASN)* 2022;17(6):851-860.PMID: 35589388. PMCID: PMC9269657. (Impact factor: 10.61; Cited by N/A; Altmetric score: 289).
28. Desai R*(g), **Park H**, Brown JD, Mohandas R, Smith SM. Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression. *Pharmacotherapy* 2022 Apr 28. doi: 10.1002/phar.2686. Epub ahead of print. PMID: 35478186. (Impact factor: 6.25; Cited by N/A; Altmetric score: 2).
29. Desai R*(g), **Park H**, Brown J, Mohandas R, Pepine C, Smith S. Comparative safety and effectiveness of aldosterone antagonists versus beta-blocker as fourth agents in patients with apparent resistant hypertension. *Hypertension* 2022 Oct; 79(10):2305-2315. doi:10.1161/HYPERTENSIONAHA.122.19280. Epub 2022 Jul 26. PMID: 35880517.

30. Yang S (g), Orlova Y, Lipe A, Boren M, Hincapie-Castillo JM, **Park H**, Chang CY, Wilson DL, Adkins L, Lo-Ciganic WH. Trends in the Management of Headache Disorders in US Emergency Departments: Analysis of 2007-2018 National Hospital Ambulatory Medical Care Survey Data. *Journal of Clinical Medicine* 2022 Mar 3;11(5):1401. Doi: 10.3390/jcm11051401. PMID: 35268492; PMCID: PMC8910868. (Impact factor: 4.96; Cited by N/A; Altmetric score: 36).
31. Desai R* (g), **Park H**, Brown J, Smith S. Risk of obstructive sleep apnea in adults with resistant hypertension. *Pharmacoepidemiology* 2022;1(1):26-32. <https://doi.org/10.3390/pharma1010003> (Impact factor: 2.89; Cited by N/A; Altmetric score: 2).
32. Wang C (g), **Park H**, Heldermon C, Vouri S, Brown J. Patient out-of-pocket and payer costs for pegfilgrastim originator and biosimilar in commercially insured patients with cancer. *Journal of Managed Care & Specialty Pharmacy* 2022; 28(7):795-802. PMID: 35737859. (Impact factor: 2.713; Cited by N/A; Altmetric score: N/A).
33. **Park H**, **Lo-Ciganic W**, Huang J, Wu Y, Henry L, Peter J, Sulkowski M, Nelson D. Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. *Hepatology* 2022 Aug;76(2):483-491. doi: 10.1002/hep.32347. Epub 2022 Feb 3. PMID: 35034373; PMCID: PMC9287493. (Impact factor: 17.30; Cited by N/A; Altmetric score: 21).
34. Kang H*(p), Lo-Ciganic WH, DeRemer CE, Dietrich EA, Huang PL, **Park H**. Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study. *Clinical Pharmacology and Therapeutics*. 2022 Jul;112(1):133-145. Doi: 10.1002/cpt.2611. Epub 2022 May 2. PMID: 35420702. (Impact factor: 6.90; Cited by N/A; Altmetric score: 8).
35. Song H*(p), Heo J, Wilson D, Shao H, **Park H**. A national catalog of SF-6D utility scores for chronic conditions in the United States. *Value in Health* 2022; 30:S1098-3015(22)00122-X. doi: 10.1016/j.jval.2022.02.011. Epub ahead of print. PMID: 35367137. (Impact factor: N/A; Cited by N/A; Altmetric score: 3).
36. Lo-Ciganic W, Hincapie-Castillo J, Wang T, Ge Y, Jones BL, Huang JL, Chang CY, Wilson DL, Lee JK, Reisfield GM, Kwok CK, Delcher C, Nguyen KA, Zhou L, Shorr RI, Guo J, Marcum ZA, Harle CA, **Park H**, Winterstein A, Yang S (g), Huang PL, Adkins L, Gellad WF. Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group-based multi-trajectory models. *Addiction* 2022; 117(7):1982-1997. Doi: 10.1111/add.15857. PMID: 35224799. (Impact factor: 7.26; Cited by 1; Altmetric score: 12).
37. DeRemer C, Dietrich E, Kang H*(p), Huang P, Lo-Ciganic W, **Park H**. Comparison of effectiveness and safety of low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism. *Journal of Internal Medicine* 2022; 291(6):877-885. doi: 10.1111/joim.13462. PMID: 35192737. (Impact factor: 13.07; Cited by 1; Altmetric score: 4).
38. Choi Y (g), Cody M, Christian H, **Park H**. Winterstein A. Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab

- prophylaxis qualifier in the American Academy of Pediatrics Guidelines. *European Journal of Pediatrics* 2022, 181(2); 841-845. doi: 10.1007/s00431-021-04233-6. Epub 2021 Aug 7. PMID: 34365543; PMCID: PMC8349231. (Impact factor: 3.86; Cited by 1; Altmetric score: 8).
39. Unigwe I*(g), Yang S (g), Song H, Lo-Ciganic W, Hincapie-Castillo J, Cook R, **Park H**. Trends in sexually transmitted infections in the United States ambulatory care clinics from 2005-2016. *Journal of Clinical Medicine* 2021, 24;11: doi: 10.3390/jcm11010071. PMID: 35011812. PMCID: PMC8745575. (Impact factor: 4.96; Cited by 1; Altmetric score: 1).
 40. Wang C, Heldermon C, Vouri S, **Park H**, Sheeler S, Ramnaraigh B, Dang N, Brown J. Trends in use of granulocyte colony-stimulating factor following introduction of biosimilars among adults with cancer and Commercial or Medicare insurance from 2014 to 2019. *JAMA Network Open* 2021;4(11):e2133474. doi: 10.1001/jamanetworkopen.2021.33474. PMID: 34812849. PMCID: PMC8611485. (Impact factor: 13.35; Cited by N/A; Altmetric score: 6).
 41. Song H*(p), Blake K, Wilson D, Winterstein A, **Park H**. Health-related quality of life of mild, moderate, and severe asthma. *Journal of Asthma & Allergy* 2021. Doi: 10.2147/jaa.s316278. PMID: 34349523. PMCID: PMC8326771. (Impact factor: 3.03; Cited by 2; Altmetric score: 20).
 42. Kamara M, Veronica R, Somboonwit C, **Park H**, Seneadza N, Zhi Z, Jayaweera D, Emmanuel T, Cook R. Self-reported hepatitis C testing among people living with human immunodeficiency virus. *Heliyon* 2021. Doi: 10.1016/j.heliyon.2021.e07727. PMID: 34409188. PMCID: PMC8361055. (Impact factor: 3.78; Cited by N/A; Altmetric score: 4).
 43. **Park H**, Jiang X (g)*, Song H (p)*, Lo Re V, Childs-Kean L, Lo-Ciganic W, Cook R, Nelson D. The impact of direct-acting antiviral therapy on end stage liver disease among individuals with chronic hepatitis C and substance use disorders. *Hepatology* 2021 Feb. doi:10.1002/hep.31732. PMID: 33544904. PMCID: PMC8339171. (Impact factor: 17.30; Cited by 5; Altmetric score: 4).
 44. Riaz M (g)*, Smith S, Dietrich E, Pepine C, **Park H**. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in the treatment of patients with systolic heart failure: A retrospective cohort study. *Pharmacotherapy* 2021. Doi: 10.1002/phar.2610. PMID: 34170559. (Impact factor: 6.25; Cited by 1; Altmetric score: 10).
 45. Jiang X (g)*, Martin S, Diaby V, Lo-Ciganic W, Parker R, **Park H**. Healthcare utilization and costs associated with all-oral direct acting antivirals for chronic hepatitis C infected patients with substance use disorders. *Journal of Managed Care & Specialty Pharmacy* 2021;27(10):1388-1402. Doi: 10.18553/jmcp.2021.27.10.1388. PMID: 34595949. PMCID: PMC8968723. (Impact factor: 2.34; Cited by N/A; Altmetric score: N/A).
 46. Boemmel-Wegmann V (g)*, Brown J, Diaby V, Huo J, Silver N, **Park H**. Healthcare utilization and costs associated with systemic metastatic melanoma therapies in the United States. *JCO Oncology Practice* 2021 Jul 6:OP2100140. Doi: 10.1200/OP.21.00140. Online ahead of print. PMID: 34228489. (Impact factor: 3.59; Cited by N/A; Altmetric score: 12).

47. Yeo Y, Hwang J, Jeong D, Dang N, Kam L, Henry L, **Park H**, Chenug R, Nguyen M. Surveillance of patients with cirrhosis remains suboptimal in the United States. *Journal of Hepatology* 2021. doi: 10.1016/j.jhep.2021.04.042. PMID: 33965477. (Impact factor: 25.083; Cited by N/A; Altmetric score: N/A).
48. Jiang X (g)*, Parker R, Martin S, Lo-Ciganic W, Diaby V, Henry L, **Park H**. Cascade of hepatitis C virus care among patients with substance use disorders. *American Journal of Preventive Medicine* 2021 Oct;61(4):576-584. doi: 10.1016/j.amepre.2021.04.013. Epub 2021 Jun 29. PMID: 34210584; PMCID: PMC8455419. (Impact factor: 6.60; Cited by N/A; Altmetric score: 4).
49. Jiang X (g)*, Song H (p)*, Wang W (g)*, Henry L, Childs-Kean L, Lo Re V, **Park H**. The use of all-oral direct acting antivirals in hepatitis C virus infected patients with substance use disorders. *Journal of Managed Care & Specialty Pharmacy* 2021; 27(7):873-881. Doi:10.18553/jmcp.2021.27.7.873. PMID: 34185563. PMCID: PMC8244773. (Impact factor: 2.34; Cited by 1; Altmetric score: N/A).
50. Jeon N (g), **Park H**, Segal R, Brumback B, Winterstein A. Non-steroidal anti-inflammatory drug-associated acute kidney injury: Does short-term NSAID use pose a risk in hospitalized patients. *European Journal of Clinical Pharmacology* 2021 ep;77(9):1409-1417. doi: 10.1007/s00228-021-03121-0. Epub 2021 Mar 27. PMID: 33772627. (Impact factor: 3.06; Cited by 1; Altmetric score: 2).
51. Venugopalan V, Crawford R, Ho K, Premraj S, Garg M (g)*, **Park H**, Klinker K, Cherabuddi K, Desear K. Resource over-utilization in hospitalized patients with uncomplicated skin and soft tissue infections. *Journal of Pharmacy Practice* 2021 Oct;35(5):675-679. doi: 10.1177/08971900211000216. Epub 2021 Mar 23. PMID: 33752488. (Impact factor: N/A; Cited by N/A; Altmetric score: 1).
52. Alalwan A (g), Friedman J, **Park H**, Segal R, Brumback B, Hartzeman A. US National trends in bariatric surgery: A decade of study. *Surgery* 2021; S0039-6060(21)00094-5. doi: 10.1016/j.surg.2021.02.002. PMID: 33714616. (Impact factor: 4.35; Cited by 7; Altmetric score: 25).
53. Oueini R, Goodin A, Vouri S, **Park H**, Lo-Ciganic W, Hincapie-Castillo J. Changes in Schedule II opioid volume dispensed in a private health plan following Florida's acute pain opioid restriction law. *Journal of Managed Care & Specialty Pharmacy* 2021 Jun;27(6):779-784. Doi: 10.18553/jmcp.2021.27.6.779. PMID: 34057389. (Impact factor: 2.34; Cited by 1; Altmetric score: 4).
54. **Park H**, Song H (p)*, Jiang X (g)*, Henry L, Cook R, Nelson D. Direct-acting antiviral treatment use remains low among Florida Medicaid beneficiaries with chronic hepatitis C. *Hepatology Communications* 2021;5(2):203-216. <https://doi.org/10.1002/hep4.1634>. PMID: 33553969. PMCID: PMC7850300. (Impact factor: 5.70; Cited by 5; Altmetric score: 4).
55. Wang W (g)*, Lo Re V, Guo Y, Xiao H, Brown J, **Park H**. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the U.S. *Alimentary Pharmacology & Therapeutics* 2020;52(10):1592-1602. PMID: 32931606. PMCID: PMC8018. (Impact factor: 9.52; Cited by 4; Altmetric score: 3).

56. Song H (p)*, Blake K, Wilson D, Winterstein A, **Park H**. Medical costs and productivity loss of mild, moderate, and severe asthma in the United States, 2010-2017. *Journal of Asthma & Allergy* 2020;13:545-555. PMID: 33149626. PMCID: PMC7605920. (Impact factor: 3.03; Cited by 4; Altmetric score: 8).
57. Song H (p)*, Squires P (g), Wilson D, Lo-Ciganic W, Cook R, **Park H**. Trends in HIV pre-exposure prophylaxis (PrEP) prescribing in the United States, 2012-2018. *The Journal of the American Medical Association (JAMA)* 2020;324(4):395-397. [Doi:10.1001/jama.2020.7312](https://doi.org/10.1001/jama.2020.7312). PMID: 32720996. PMCID: PMC7388017. (Impact factor: 157.34; Cited by 4; Altmetric score: 6).
58. Choi Y (g), Meissner C, Hampp C, **Park H**, Brumback B, Winterstein A. Calibration of chronic lung disease severity as a risk factor for respiratory syncytial virus hospitalization. *Journal of the Pediatric Infectious Diseases* 2021;10(3): 317-325. [Doi: 10.1093/jpids/piaa107](https://doi.org/10.1093/jpids/piaa107). PMID: 32978942. (Impact factor: 5.24; Cited by 1; Altmetric score: 1).
59. Desai R*(g), Dietrich E, **Park H**, Smith S. Out-of-pocket payment for ambulatory blood pressure monitoring among commercially-insured in the United States. *American Journal of Hypertension* 2020;33(11):999-1002. <https://doi.org/10.1093/ajh/hpaa120>. PMID: 32930343. PMCID: PMC7608520. (Impact factor: 3.08; Cited by 1; Altmetric score: 2).
60. Dawwas G*(g), Dietrich E, Davis K, **Park H**. Comparative effectiveness and safety of direct acting oral anticoagulants and warfarin in patients with venous thromboembolism and active cancer. *Clinical Therapeutics* 2020;42(9): e161-e176. <https://doi.org/10.1016/j.clinthera.2020.06.022>. PMID: 32768247. (Impact factor: 3.64; Cited by 1; Altmetric score: N/A).
61. Desai R* (g), **Park H**, Dietrich E, Smith S. Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially-insured in the U.S., 2008-2017. *International Journal of Cardiology Hypertension* 2020: 6; 100033. <https://doi.org/10.1016/j.ijchy.2020.100033>. PMID: 33447762. PMCID: PMC7803015. (Impact factor: N/A; Cited by 5; Altmetric score: 3).
62. Song H*(p), Jiang X*(g), Henry L, Nguyen M, **Park H**. The impact of proton pump inhibitor uses on liver cancer and mortality in patients with chronic liver diseases: a systematic review and meta-analysis. *European Journal of Clinical Pharmacology* 2020; 76(6):851-866. DOI: 10.1007/s00228-020-02854-8. PMID: 32172363. PMCID: PMC7244371. (Impact factor: 3.06; Cited by 8; Altmetric score: 1).
63. Boemmel-Wegmann* (g), Lo Re V, **Park H**. Early treatment uptake and cost burden of hepatitis C therapies among newly diagnosed hepatitis C patients with a particular focus on HIV coinfection. *Digestive Diseases and Sciences* 2020;65:3159-3174 <https://doi.org/10.1007/s10620-019-06037-z>. PMID: 31938995. PMCID: PMC7358122. (Impact factor: 3.49; Cited by 1; Altmetric score: 2).
64. Chang C (g), **Park H**, Malone D, Wang C (g), Yeh Y, Boemmel-Wegmann (g), Lo-Ciganic W. Immune checkpoint inhibitors and risk of immune-related adverse events in patients with advanced melanoma: A systematic review and network meta-analysis. *JAMA Open* 2020;3(3):e201611. [Doi:10.1001/jamanetworkopen.2020.1611](https://doi.org/10.1001/jamanetworkopen.2020.1611). PMCID:

32211869. PMCID: PMC7097702. (Impact factor: 13.35; Cited by 28; Altmetric score: 18).

65. **Park H**, Wang W*(g), Henry L, Nelson D. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the United States. *Hepatology* 2019;69(3):1032-1045. Doi: 10.1002/hep.30303. PMID: 30289989. PMCID: PMC6393174. (Impact factor: 17.30; Cited by 27; Altmetric score: 16). ***selected for editorial highlights**.
66. Choi Y (g), **Park H**, Hampp C, Brumback B, Meissner C, Yan L, Roussos-Ross D, Zhu Y, Winterstein A. Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. *Pharmacoepidemiology and Drug Safety* 2019. Doi: 10.1002/pds.4923. PMID: 31737976. (Impact factor: 2.73; Cited by N/A; Altmetric score: 3).
67. Dawwas G*(g), Leonard C, Garg M (g), Vouri S, Smith S, **Park H**. Twelve-years trends in Pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. *Diabetes, Obesity and Metabolism* 2020:1-6. <https://doi.org/10.1111/dom.13949>. PMID: 31903713. (Impact factor: 6.41; Cited by 2; Altmetric score: 8).
68. Dietrich E, Desai R*(g), Garg M*(g), **Park H**, Smith S. Reimbursement of ambulatory blood pressure monitoring in the U.S. commercial insurance market place. *Journal of Clinical Hypertension* 2020;22(1):6-15. Doi: 10.1111/jch.13772. PMID: 31873973. PMCID: PMC7011780. (Impact factor: 2.89; Cited by 4; Altmetric score: 7).
69. Dawwas G*(g), Dietrich E, Winchester D, Winterstein A, Segal R, **Park H**. Comparative effectiveness of ticagrelor versus prasugrel for the prevention of recurrent cardiovascular diseases and adverse bleeding outcomes in patients with acute coronary syndrome. *Pharmacotherapy* 2019;39(9):912-920. Doi: 10.1002/phar.2311. PMID: 31332815. (Impact factor: 6.25; Cited by 6; Altmetric score: 6).
70. Zou B, Yeo Y, Jeong D, **Park H**, Sheen E, Lee D, Linda H, Garcia G, Ingelsson E, Cheung R, Nguyen M. A nationwide study of inpatient admissions, mortality, and costs for patients with cirrhosis from 2005-2015 in the U.S. *Digestive Diseases and Sciences* 2019. <https://doi.org/10.1007/s10620-019-05869-z>. PMID: 31598919. (Impact factor: 3.49; Cited by 9; Altmetric score: 3).
71. Dawwas G*(g), Smith S, Dietrich E, Lo-Ciganic W, **Park H**. Comparative effectiveness and safety of apixaban compared to warfarin in patients with venous thromboembolism: A retrospective cohort analysis. *American Journal of Health-System Pharmacy* 2020;2477(3):188-195. Doi: 10.1093/ajhp/zxz307. PMID: 31974557. (Impact factor: 2.98; Cited by 7; Altmetric score: 2).
72. **Park H**, Dawwas G*(g), Liu X*(p), Nguyen M. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease in a large cohort of U.S. population. *Journal of Internal Medicine* 2019. Doi: 10.1111/joim.12964. PMID: 31359543. PMCID: PMC6851415. (Impact factor: 13.06; Cited by 28; Altmetric score: 15).
73. Dawwas G*(g), Brown J, Dietrich E, **Park H**. Comparative effectiveness and safety of apixaban and rivaroxaban for the prevention of recurrent venous thromboembolism and

bleeding in patients with venous thromboembolism. *The Lancet Haematology* 2019;6(1): e20-28. Doi:10.1016/S2352-3026(18)30191-1. PMID: 30558988. (Impact factor: 30.15; Cited by 47; Altmetric score: 49). ***received 2020 American College of Clinical Pharmacy Outstanding Paper of the Year Award.**

74. **Park H**, Liu X (p), Henry L, Harman J, Ross E. Trends in anemia care in non-dialysis dependent chronic kidney disease patients in the United States (2005-2015). *BMC Nephrology* 2018. Doi:10.1186/s12882-018-1119-7. PMID: 30413150. PMCID: PMC6230235. (Impact factor: 2.56; Cited by 20; Altmetric score: 7).
75. Song HJ*(p), **Park H**, Park S, Kwon JW. The association between proton pump inhibitor use and the risk of tuberculosis: a case-control study. *Pharmacoepidemiology and Drug Safety* 2019. Doi: 10.1002/pds.4773. PMID: 30920070. (Impact factor: 2.89; Cited by 1; Altmetric score: 5).
76. Song H*(p), **Park H**, Seo HJ. The association between proton pump inhibitor use and risk for tuberculosis: A systematic review. *International Journal of Tuberculosis and Lung Disease* 2019;23(8):943-951. Doi: 10.5588/ijtld.18.0585. PMID: 31533885. (Impact factor: 3.43; Cited by 2; Altmetric score: N/A).
77. Dawwas G*(g), Smith S, **Park H**. Cardiovascular outcomes of sodium glucose cotransporter-2 in patients with Type 2 diabetes. *Diabetes, Obesity and Metabolism* 2019;21(1):28-36. Doi: 10.1111/dom.13477. PMID: 30039524. (Impact factor: 6.41; Cited by 36; Altmetric score: 17).
78. Nguyen A, **Park H**, Nguyen P, Sheen E, Kim Y, Nguyen M. Rising inpatient encounters and economic burden for patients with non-alcoholic fatty liver disease in the United States. *Digestive Diseases and Sciences* 2019;64(3):698-707. Doi: 10.1007/s10620-018-5326-7. PMID: 30327963. (Impact factor: 3.19; Cited by 12; Altmetric score: N/A).
79. Dawwas G*(g), Smith S, **Park H**. Risk of heart failure hospitalization among users of Dipeptidyl Peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonist. *Cardiovascular Diabetology* 2018;17:102. Doi: 10.1186/s12933-018-0746-4. PMID: 30016946. PMCID: PMC6048850. (Impact factor: 8.95; Cited by 16; Altmetric score: N/A).
80. Zou B, Yeo Y, Jeong D, Sheen E, **Park H**, Nguyen P, Hsu Y, Garcia G, Nguyen M. Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness. *Scientific Report* 2018;9969: doi:10.1038/s41598-018-28317-w. PMID:29967363. PMCID: PMC6028654. (Impact factor: 4.99; Cited by 5; Altmetric score: 1).
81. Dave C (g), Winterstein A, **Park H**, Cook R, Hartzema A. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. *Journal of Affective Disorders* 2018;238:542-546. Doi: 10.1016/j.jad.2018.06.021. PMID: 29936394. (Impact factor: 6.53; Cited by 13; Almetric score: 6).
82. **Park H**, Jeong D, Nguyen P, Henry L, Hoang J, Kim Y, Sheen E, Nguyen M. Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. *PlosOne* 2018;13(4): e0196452:

doi.org/10.1371/journal.pone.0196452. PMID: 30566488. PMCID: PMC6300255.
(Impact factor: 3.75; Cited by N/A; Altmetric score: N/A).

83. Jiang X*(g), Xiao H, Segal R, Mobley W, **Park H**. Trends in readmission rates, hospital charges and mortality for patients with chronic obstructive pulmonary disease (COPD) in Florida from 2009 to 2014. *Clinical Therapeutics* 2018;40(4): 613-626. Doi: 10.1016/j.clinthera.2018.03.006. PMID: 29609879. (Impact factor: 3.64; Cited by 10; Altmetric score: 3).
84. **Park H**, Chen C (g), Wang W*(g), Henry L, Cook R, Nelson D. Hepatitis C virus infection increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. *Hepatology* 2018;67(2):492-504. Doi: 10.1002/hep.29505. PMID: 28873225. PMCID: PMC5814730. (Impact factor: 17.298; Cited by 42; Altmetric score: 27). ***selected for editorial highlights.**
85. Younossi Z, **Park H**, Dieterich D, Saab S, Ahmed A, Gordon S. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all oral regimes good value to society? *Liver International* 2017;37(5):662-668. Doi: 10.1111/liv.13298. PMID: 27804195. (Impact factor: 8.75; Cited by 17; Altmetric score: 1).
86. **Park H**, Adeyemi A*(p), Wang W*(g), Roane T. Impact of a telephonic outreach program on medication adherence in Medicare Prescription Drug (MAPD) Plan beneficiaries in Florida. *Journal of the American Pharmacist Association (JAPHA)* 2017;57(1):62-66. Doi: 10.1016/j.japh.2016.07.006. PMID: 27777074. (Impact factor: 2.12; Cited by 5; Altmetric score: 7).
87. Younossi Z, **Park H**, Dieterich D, Saab S, Ahmed A, Gordon S. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The Quality-adjusted cost of care. *Medicine* 2016;95(41) p e5048 doi: 10.1097/MD.0000000000005048. PMID: 27741116. PMCID: PMC5072943. (Impact factor: 1.82; Cited by 25; Altmetric score: 1).
88. Younossi Z, **Park H**, Ahmed A, Gordon S, Fergusson J, Dietrich D, Saab S. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naïve patients with hepatitis C. *American Journal of Managed Care* 2016;22(5): SP205-SP211. PMID: 27266950. (Impact factor: 3.25; Cited by 41; Altmetric score: 9).
89. Younossi Z, **Park H**, Henry L, Adeyemi A (p), Stepanova M. The extra-hepatic manifestations of hepatitis C – a meta-analysis of prevalence rates, effects on patient-reported outcomes economic burden. *Gastroenterology* 2016;150(7):1599-1608. doi: 10.1053/j.gastro.2016.02.039. PMID: 26924097. (Impact factor: 33.88; Cited by 226; Altmetric score: 19).
90. **Park H**, Adeyemi A*(p), Rascati KL. Direct medical costs and utilization of pneumonia in the United States: An analysis of 2007-2011 Medical Expenditure Panel Survey (MEPS). *Clinical Therapeutics* 2015;37(7):1466-1476. doi: 10.1016/j.clinthera.2015.04.013. PMID: 26001310. (Impact factor: 3.64; Cited by 24; Altmetric score:2).
91. **Park H**, Adeyemi A*(p), Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus

- infection. *Journal of Viral Hepatitis* 2015;22(11):897-905. doi: 10.1111/jvh.12413. PMID: 25904153. (Impact factor: 3.52; Cited by 65; Altmetric score: 4).
92. **Park H**, Rascati KL, Keith MS. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large US dialysis organizations. *Journal of Managed Care Pharmacy* 2015;21(6):507-514. doi: 10.18553/jmcp.2015.21.6.507. PMID: 26011552. (Impact factor: 2.34; Cited by 3; Altmetric score: 2)
93. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. Health costs and outcomes associated with Medicare Part D cost-sharing. *Journal of Managed Care Pharmacy* 2015;21(10):956-964. doi: 10.18553/jmcp.2015.21.10.956. PMID: 26402394. (Impact factor: 2.34; Cited by 4; Altmetric score: N/A)
94. Younossi Z, **Park H**, Saab S, Ahmed A, Dieterich D, Gordon S. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimen in patients with chronic hepatitis C virus genotype 1 infection. *Alimentary Pharmacology & Therapeutics* 2015;41(6):544-563. doi: 10.1111/apt.13081. PMID: 25619871. (Impact factor: 9.52; Cited by 100; Altmetric score:17).
95. Saab S, Gordon S, **Park H**, Sulkowski M, Ahmed A, Younossi Z. Cost effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C genotype 1 infection. *Alimentary Pharmacology & Therapeutics* 2014;40(6):657-675. doi: 10.1111/apt.12871. PMID: 25065960. (Impact factor: 9.52; Cited by 48; Altmetric score: 7).
96. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. Adherence and persistence to prescribed medication therapy among Medicare Part D beneficiaries on dialysis: Comparisons of benefit type and benefit phase. *Journal of Managed Care Pharmacy* 2014;20(8):862-876. doi: 10.18553/jmcp.2014.20.8.862. PMID: 25062080. (Impact factor: 14.79; Cited by N/A; Altmetric score: N/A)
97. Sterling KL, Ford KH, **Park H**, McAlister AL. Scales of smoking-related self-efficacy, belief, and intention: assessing measurement invariance among intermittent and daily high school smokers. *American Journal of Health Promotion* 2014;28(5):310-315. Doi: 10.4278/ajhp.121009-QUAN-490. PMID: 23941100. (Impact factor: 2.96; Cited by 7; Altmetric score: N/A).
98. Sterling KL, Ford KH, **Park H**, Diamond P, McAlister AL. Assessing the invariance of smoking-related self-efficacy, beliefs, and intention among high school current smokers. *Substance Use and Misuse* 2013;48(7):477-483. doi: 10.3109/10826084.2013.778276. PMID: 23647165. (Impact factor: 2.36; Cited by 1; Altmetric score: N/A).
99. **Park H**, Park C, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 [DPP-4] inhibitors in type 2 diabetes: Meta-analysis. *Annals of Pharmacotherapy* 2012;46(11):1453-1469. doi: 10.1345/aph.1R041. PMID: 23136353. (Impact factor: 3.46; Cited by 68; Altmetric score: 1).
100. Tiwana S, Rascati KL, **Park H**. Cost-effectiveness of expanded newborn screening in Texas. *Value Health* 2012;15(5):613-621. doi: 10.1016/j.jval.2012.02.007. PMID: 22867769. (Impact factor: 5.10; Cited by 20; Altmetric score:2).

101. **Park H**, Rascati KL, Prasla K, McBayne T. Evaluation of healthcare costs and utilization patterns for patients with gout. *Clinical Therapeutics* 2012;34(3):640-652. doi: 10.1016/j.clinthera.2012.01.020. PMID: 22381710. (Impact factor: 3.64; Cited by 34; Altmetric score: 1)
102. **Park H**, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R. Cost-effectiveness of lanthanum carbonate vs. sevelamer hydrochloride in patients with end-stage renal disease: A US payer perspective. *Value Health* 2011;14:1002-1009. doi: 10.1016/j.jval.2011.05.043. PMID: 22152168. (Impact factor: 5.10; Cited by 19; Altmetric score: 3)
103. **Park H**, Yang SW, Choi YW, et al. In vitro skin penetration and pharmacodynamic evaluation of prostaglandin E1 ethyl ester, a vasoactive prodrug of prostaglandin E1, formulated into alcoholic hydrogels. *Pharmazie* 2006;61:933-937.
104. Yang S (g), Yong J, Lee H, Kim H, **Park H**, Choi H. External lyogel formulation of prostaglandin E1 ethyl ester. *Journal of Korean Pharmaceutical Sciences* 2004;34:107-114. [Korean]
105. Kim H, Lee S, Choi S, **Park H**, et al. Improved dissolution characteristics of ibuprofen employing self-microemulsifying drug delivery system and their bioavailability in rats. *Journal of Korean Pharmaceutical Sciences* 2002;32:27-33. [Korean]

Submitted:

106. Desai R* (g), Unigwe I, Riaz M, Smith S, Shukla A, Mohandas R, Jeon N, **Park H**. Comparative safety of long-acting versus short-acting erythropoiesis-stimulating agents among patients undergoing hemodialysis. *Clinical Pharmacology and Therapeutics* [submitted]
107. Riaz M (g)*, Guo J, Dietrich E, Smith S, Winchester D, **Park H**. Comparative genitourinary safety of sodium glucose co-transporter-2 inhibitors among patients with heart failure with preserved ejection fraction: A cohort study. *American Journal of Cardiovascular Drugs* [revision]
108. Chang S (g)*, Wang G, Wang Y, Kang H, **Park H**. Cost-effectiveness analysis of early versus delayed use of abemaciclib combination therapy for patients with high-risk HR+/HER2- early breast cancer. *JMCP* [submitted]
109. Unigwe I (g)*, Goodin A, Lo-Ciganic W, Cook R, Janelle J, **Park H**. Trajectories of pre-exposure prophylaxis (PrEP) and risks of HIV and sexually transmitted infection. *JAMA Internal Medicine* [submitted]
110. Hernandez-Con P (g)*, Desai R (g), Nelson D, Park H. Association of oral direct acting antiviral treatment with development of Parkinson's disease in patients with chronic hepatitis C virus. *Parkinsonism and Related Disorders* [revision]

The most up-to-date list of articles can be accessed in

- (a) Google Scholar: <https://tinyurl.com/hpark-google scholar>
- (b) NCBI: <https://www.ncbi.nlm.nih.gov/myncbi/1Fi2ensYbNxQd/bibliography/public/>

Editorials

1. **Park H**, Rascati KL. Comparing two cost-effectiveness studies of statins for the primary prevention of cardiovascular disease: Are statins cost-effective from a Korean health system perspective? *Clinical Therapeutics* 2009;31:2916-2918.

Letters

1. Dawwas G (g), Brown J, Dietrich E, **Park H**. Can apixaban prevent venous thromboembolism better than rivaroxaban? *The Lancet Haematology-D-19-0010* 2019.

Non-Peer-Reviewed

1. Kim D, **Park H**, Rascati KL. Medication Adherence with risperidone in Texas Medicaid patients with schizophrenia. *ISPOR Connections*, 2012;Jan.
2. **Park H**, Dasgupta A, Rascati KL. Current Pharmacoeconomic issues and drug reform in South Korea. *ISPOR Connections*, 2009;Aug:11.

POSTER PRESENTATIONS (peer-reviewed; reverse chronological order; underline denotes corresponding author; g denotes student; p denotes postdoc)

1. **Park H**, Lo-Ciganic W, Huang J, Wu Y, Wilson D, Henry L, Peter J, Sulkowski M, Nelson DR. Evaluation of Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure Among Patients with Chronic Hepatitis C Infection. Asian Pacific Association for the Study of the Liver Single Topic Conference (APASL STC) 2023. 21-23 September 2023, Busan, Korea.
2. Kang HR_(p), Hernandez-Con P_(g), Heo JH, Wilson DL, Blake KV, Lang JE, **Park H**. Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States. Poster presentation at 2023 ICPE. 2023 August 23-27, Halifax, Nova Scotia, Canada
3. Chang SH, Cabrera R, Guo J, Wilson D, Park C, **Park H**. Real-world effectiveness of all-oral direct-acting antivirals among patients with hepatitis C virus-related hepatocellular carcinoma. Poster presentation at 2023 ICPE. 2023 August 23-27, Halifax, Nova Scotia, Canada
4. Hernandez-Con P, Wilson DL, Smith S, Norse AB, **Park H**. The Cascade of Care in Individuals Screened for Hepatitis C Virus Infection in Emergency Departments. Poster presentation at 2023 ICPE. August 23-27, 2023. Halifax, Nova Scotia, Canada.
5. Riaz M, Smith S, Winchester DE, Guo J, Dietrich E, **Park H**. Comparative effectiveness and costs of sacubitril/valsartan versus angiotensin receptor blockers in heart failure with preserved ejection fraction. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 May 7-10, Boston, MA
6. Riaz M, Smith S, Winchester DE, Guo J, Dietrich E, **Park H**. Utilization trends of pharmacotherapies among patients with heart failure with preserved ejection fraction. ISPOR 2023 May 7-10, Boston, MA
7. Riaz M, Smith S, Winchester DE, Guo J, Dietrich E, **Park H**. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction: a real-world study. ISPOR 2023 May 7-10, Boston, MA

8. Unigwe I, Goodin A, Lo-Ciganic W, Cook R, **Park H**. Trends of adherence to Pre-exposure Prophylaxis (PrEP) and risk of HIV incidence. ISPOR 2023 May 7-10, Boston, MA
9. Chang SH, Wang, HM, Wang Y, Wilson DL, Shao H, **Park H**. Cost-Effectiveness Analysis of Early Versus Delayed Use of Abemaciclib Combination Treatment in Patients with HR+/HER2- High-Risk Early Breast Cancer: A US Payer Perspective. Value in Health. 25(7):S369. <https://doi.org/10.1016/j.jval.2022.04.432>. (Poster presentation at the ISPOR 2022, May 15-18, 2022) Washington D.C., USA
10. Unigwe, I, Cook R, Janelle J, **Park H**. Screening and monitoring of HIV Pre-exposure prophylaxis use among commercially insured patients, 2016-2020. 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). August 24-28, 2022. Copenhagen, Denmark
11. Hernandez-Con P_(g), Song HJ_(p), Unigwe I_(g), Riaz M_(g), Ourhaan N, Jiang X_(g), Wilson D, Joseph A_(g), **Park H**. The care cascade of hepatitis C virus in the direct-acting antiviral era: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2022; 31, pp. 403-403. (Poster presentation at the 2022 38th ICPE, August 24-28, 2022) Copenhagen, Denmark
12. Unigwe I, Song H, Cook R, **Park H**. Screening and monitoring testing of HIV pre-exposure prophylaxis use among commercially insurance patients, 2016-2020. at the 38th ICPE, August 24-28, 2022, Copenhagen, Denmark
13. Chang C-Y_(g), Hincapie-Castillo JM, **Park H**, Heldermon CD, Diaby V, Yang S_(g), Wilson DL, Lo-Ciganic WH. Trends and Characteristics Associated with Nonadherence to Antidepressants among Breast Cancer Survivors with Depression. Pharmacoepidemiol Drug Saf. 2022;31(Suppl. 2):3-628. doi. 10.1002/pds.5518. Presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), August 24-28, 2022, Copenhagen, Denmark
14. Kang H (p), Jones B, Lo-Ciganic W, DeRemer C, Dietrich E, Huang P, Murphy M, **Park H**. Adherence Trajectories of Extended Direct-Acting Oral Anticoagulants and Risk of Recurrent Venous Thromboembolism and Major Bleeding: A Retrospective Cohort Study. Blood. 2021 ;138(Supplement 1):4059.
15. Song H (p), Jones B, Squires P, Cook B, **Park H**. Effectiveness of HIV Pre-exposure prophylaxis for prevention of HIV: A retrospective cohort analysis. Poster presentation at the ISPOR 2022 May 15-18. Washington DC.
16. Ndai A (g), Jiao T, Aroza R, **Park H**, Vouri S. Cost-effectiveness of tenofovir/lamivudine/efavirenz versus tenofovir/lamivudine/dolutegravir for preventing mother-to-child transmission of HIV in Nigeria. Poster presentation at the ISPOR 2022 May 15-18. Washington DC.
17. Chang SH, Wang G, Wang Y, Wilson D, Shao H, **Park H**. Cost-effectiveness analysis of early versus delayed use of abemaciclib combination treatment in patients with HR+/HER2- high early breast cancer: A US payer perspective. Poster presentation at the ISPOR 2022 May

18. Unigwe I, Yang S (g), Song HJ, Lo-Ciganic WH, Cook R, **Park H**. Trends in Sexually Transmitted Infections in United States Ambulatory Care Clinics from 2005-2016 [Lightning Presentation]. 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) All Access (Virtual meeting). August 23-25, 2021. *Pharmacoepidemiol Drug Saf.* 2021;30 Suppl 1:3-439. PMID: 34431155 <https://doi.org/10.1002/pds.5305>.
19. Yang S (g), Lipe A, Boren M, Hincapie-Castillo JM, Brown JD, **Park H**, Guo J, Chang C, Wilson DL, Adkins L, Lo-Ciganic W. Trends in the management of primary headache in US emergency departments: Analysis of 2007-2018 NHAMCS data. *Pharmacoepidemiol Drug Saf.* 2021; 30(Supplement 1). (Poster presentation at the 2021 Virtual 37th ICPE, August 23-25, 2021)
20. Ravindra N, Faddoul N, Lo-Ciganic W, Hincapie-Castillo JM, **Park H**, Heldermon CD, Yang S (g), Wilson DL, Adkins L, Chang C. Association between Non-Adherence to Endocrine Therapy and the Risk of Recurrence among Breast Cancer Survivors: A Systematic Literature Review. *Pharmacoepidemiol Drug Saf.* 2021; 30(Supplement 1). <https://doi.org/10.1002/pds.5305>. (Poster presentation at the 2021 Virtual 37th ICPE, August 23-25, 2021)
21. Faddoul N, Ravindra N, Lo-Ciganic W, Hincapie-Castillo JM, **Park H**, Heldermon CD, Yang S (g), Wilson DL, Adkins LE, Chang C. Opioid Use Patterns among Non-metastatic Cancer Survivors: A Systematic Literature Review. *Pharmacoepidemiol Drug Saf.* 2021; 30(Supplement 1). (Poster presentation at the 2021 Virtual 37th ICPE, August 23-25, 2021)
22. Kang H, Lo-Ciganic W, DeRemer C, Dietrich E, Huang P, **Park H**. Effectiveness and Safety of Extended Anticoagulation in Patients with Venous Thromboembolism: A Retrospective Cohort Study. (2021), ISPE Annual Meeting Abstracts. *Pharmacoepidemiol Drug Saf.* 30: 3-400
23. Jiang X (g), Vouri SM, Diaby V, Lo-Ciganic W., Parker R, **Park H**. Healthcare Utilization and Costs Associated with Direct-Acting Antivirals for Patients with Chronic Hepatitis C and Substance Use Disorders. *Value in Health.* 2021 Jun 1;24:S156. ISPOR, May 2021
24. Jiang X (g), Diaby V, Vouri SM, Lo-Ciganic W, Parker R, Wang W, Henry L, **Park H**. A Budget Impact Analysis of Universal Hepatitis C Virus (HCV) Testing for Patients with Substance Use Disorders. *Value in Health.* 2021 Jun 1;24:S147-8. ISPOR, May 2021.
25. Song HJ (p), Blake K, Wilson DL, Winterstein AG, **Park H**. J7 Direct and indirect costs among patients with mild, moderate, and severe asthma in the United States. *JMCP* 2021;27(4-a Suppl):S86-S87. AMCP Virtual 2021. April 12-16.
26. Desai R (g), Smith SM, **Park H**, Risk of Obstructive Sleep Apnea in Adults with Treatment Resistant Hypertension: A Population-Based Cohort Study. *Value in Health.* 2021 Jun 1;24:S67. ISPOR, May 2021
27. Unigwe I (g) Yang S (g), Song H(p), Lo-Ciganic W, Hincapie-Castillo J, Cook R, **Park H**. Trends in sexually transmitted infections in the United States ambulatory care clinics from 2005-2016. [Poster]. University of Florida College of Pharmacy Research Showcase. April 2021

28. Desai R (g), Smith SM, Mohandas R, **Park H**, Comparative Safety Of Epoetin Versus Darbepoetin In Prevention Of Major Adverse Cardiovascular Events In Patients Undergoing Hemodialysis. ICPE All Access, September 2020
29. Yang S (g), Boren M, Lipe A, Hincapie-Castillo JM, Brown J, **Park H**, Guo S, Chang CY, Wilson DL, Adkins LE, Lo-Ciganic W. Trends and Characteristics in Opioid Analgesic Use for Migraine in US Emergency Departments: Analysis of National Hospital Ambulatory Medical Care Survey 2007-2018 Data. *Value in Health*. 2021;24(Supplement 1): S168. (Poster presentation at the 2021 ISPOR Virtual Conference)
30. Kang H (p), Lo-Ciganic W, DeRemer C, Dietrich E, Huang P, **Park H**. Effectiveness and safety of extended anticoagulation in patients with venous thromboembolism: a retrospective cohort study. 2021 ICPE 37th Annual Meeting
31. Riaz M (g) Dietrich E (g), Smith S, Pepine C, **Park H**. Effectiveness Of Sacubitril/Valsartan Versus Aldosterone Antagonists For Prevention Of Heart Failure-related and All-cause Hospitalization In Heart Failure with Reduced Ejection Fraction. ICPE all access 2021(23-24 August, 2021)
32. Goodin A, Huang J, **Park H**, Hincapie-Castillo JM, Brown J, Costales B (g), Wilson D, Lo-Ciganic W. Changes in Prevalence of High-Risk Opioid Use Quality Measures in Arizona, 2011-2018. (Published in conference proceedings; Poster presentation at the 2020 Virtual Annual Research Meeting of AcademyHealth)
33. Tasmim K(&), Goodin A, Lopez-Quintero C, **Park H**, Mora J, Lo-Ciganic W, Hincapie-Castillo JM. Increases in County-Level Opioid Prescribing in the United States despite National Declining Rates, 2012-2017. (Published in conference proceedings; Poster presentation at the 2020 Virtual Scientific Meeting of the College on Problems of Drug Dependence)
34. Hincapie-Castillo JM, Goodin A, Vouri S, Lo-Ciganic W, **Park H**. PDG33 Changes in Schedule II Oral Opioid Volume Dispensed in a Private Payer Following Florida's Acute Pain Opioid Restriction Law. *Value in Health*. 2020; 23:S135 (Poster presentation at the 2020 ISPOR Virtual Conference)
35. Boemmel-Wegmann S (g), Brown J, Diaby V, Huo J, Silver N, **Park H**. Risks of acute gastrointestinal adverse events associated with metastatic melanoma therapies: A retrospective cohort study. ICPE 36th Annual Meeting * selected as a **Spotlight Poster**.
36. Desai R (g), Smith S, Mohandas R, **Park H**. Comparative safety of epoetin versus darbepoetin in prevention of major adverse cardiovascular events in patients undergoing hemodialysis. ICPE 36th Annual Meeting * selected as a **Spotlight Poster Winner**.
37. Chang CY (g), Park H, Lo-Ciganic WH. The prevalence of sun protective behaviors across different age groups in the US population: Findings from the 2015 US Health Interview Survey. ISPOR 2020 Annual Meeting. *Value Health* 2020;29(S3):3964
38. Desai R (g), Park H, Smith S. Risk of obstructive sleep apnea in adults with treatment resistant hypertension: a population-based cohort study using administrative claims data. ISPOR 2020 Annual Meeting.

39. Song H (p), Squires P (g), Wilson D, Lo-Ciganic W, Cook R, **Park H**. Uptake of pre-exposure prophylaxis (PrEP) and type of providers among commercially-insured persons in the United States, 2012-2018. ISPOR Annual Meeting. 2020; May 16-20, Orlando, FL *Value Health* 23, S178.
40. Hincapie-Castillo, Goodin AJ, Vouri S, Lo-Ciganic W, **Park H**. Changes in schedule ii oral opioid volume dispensed in a private payer following Florida's acute pain opioid restriction law. *Value in Health* 23, S135, 2020.
41. Goodin AJ, Hincapie-Castillo, Vouri S, **Park H**, Lo-Ciganic W. Changes in prevalence of high-risk opioid use quality measures in Arizona, 2011-2018. *Academy Health*
42. Goodin AJ, Huang JL, **Park H**, Hincapie-Castillo JM, Brown JD, Costales B, Lo-Ciganic W. Trends in Controlled Substance Utilization in Arizona from 2011-2016, by Prescription Class. 2019 Addiction Health Services Research (AHSR), Salt Lake City, Utah, USA, October 16-18, 2019.
43. Smith S, Desai R (g), Dietrich E, **Park H**. Trends in ambulatory and home blood pressure monitoring use for confirmation of hypertension or resistant hypertension among the commercially-insured in the U.S., 2008-2017. 2019 American Heart Association. New Orleans, LA, September 5-9, 2019.
44. Garg M (g), **Park H**. Trends in inappropriate outpatient antibiotic use in the United States. ISPE 35th Annual Meeting, Philadelphia, PA, August 24-28, 2019.
45. Dawwas G (g), Dietrich E, Winchester D, Winterstein A, Segal R, **Park H**. Comparative effectiveness and safety of concomitant use of antiplatelets and anticoagulants in acute coronary syndrome patients with atrial fibrillation. ISPE 35th Annual Meeting, Philadelphia, PA, August 24-28, 2019.
46. Dawwas G (g), Dietrich E, **Park H**. Comparative Effectiveness and Safety of Direct Acting Oral Anticoagulants and Warfarin in Cancer Patients with Venous Thromboembolism. ISPE 35th Annual Meeting, Philadelphia, PA, August 24-28, 2019.
47. Garg M (g), **Park H**. Impact of disease severity on healthcare costs in patients with chronic hepatitis c virus infection. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
48. Chang C (g), **Park H**, Lo-Ciganic. Use of immune checkpoint inhibitors and risk of immune-related adverse events among patients with advanced melanoma: a systematic review and network meta-analysis. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
49. Chang C (g), **Park H**, Lo-Ciganic. The prevalence of sun protective behaviors across different age groups in the us population: findings from the 2015 us health interview survey. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
50. Desai RA (g), Dietrich E, Garg M, **Park H**, Smith S. Reimbursement of ambulatory blood pressure monitoring in the commercial insurance marketplace. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.

51. Desai RA (g), Dietrich E, Garg M, **Park H**, Smith S. The out-of-pocket burden of ambulatory blood pressure monitoring: a united states perspective in the commercial insurance marketplace. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
52. Jiang X (g), Wang W (g), **Park H**. All-oral direct-acting antivirals decrease liver complications in chronic hepatitis c patients with substance use disorders in the united states. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
53. Dawwas G (g), Dietrich E, **Park H**. Comparative effectiveness and safety of antiplatelets therapy in patients with type 2 diabetes and acute coronary syndrome. ISPE midyear meeting, Rome, Italy 2019.
54. **Park H**, Liu X (p), Nguyen M. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease in a large cohort of U.S. population. The American Association for the Study of Liver Disease (AASLD) of Liver Meeting, San Francisco, CA, November 9-13, 2018. Hepatology 2018;68(S1).
55. Dawwas G (g), **Park H**. Effectiveness of apixaban versus warfarin for the prevention of cardiovascular diseases and recurrent venous thromboembolism. ISPE 34th Annual Meeting, Prague, Czech. August 22nd-26th, 2018.
56. Dawwas G (g), Dietrich E, Winchester D, Winterstein A, Segal S, **Park H**. Comparative Effectiveness of Prasugrel versus Ticagrelor for the Prevention of Cardiovascular Diseases in Patients with Acute Coronary Syndrome. ISPE 34th Annual Meeting, Prague, Czech. August 22nd-26th, 2018.
57. Zou B, Yeo YH, Jeong D, Sheen E, **Park H**, Nguyen P, Hsu YC, Garcia G, Nguyen MH. 360-higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States. The Digestive Disease Week (DDW), Washington DC, June 2-5, 2018. Gastroenterology 2018; 154(6): S-1086.
58. Zou B, Yeo YH, Jeong D, Sheen D, **Park H**, Lee DH, Garcia G, Nguyen MH. The trends over time of hospital admissions, inpatient mortality rate, and hospital cost of hospitalizations associated with cirrhosis in the United States: An Analysis on the National Inpatient Sample. DDW, Washington DC, June 2-5, 2018. Gastroenterology 2018; 154(6): S-1183.
59. Zou B, Yeo YH, Jeong D, Sheen D, **Park H**, Lee DH, Garcia G, Nguyen MH. Inpatient healthcare utilization in cirrhotic patients with acute respiratory illness (ARI): an analysis on the U.S. national inpatient sample from 2005 to 2011. DDW, Washington DC, June 2-5, 2018. Gastroenterology 2018; 154(6): S-533.
60. Jiang X (g), Wang W (g), **Park H**. Uptake of all-oral direct acting antivirals in hepatitis C virus-infected patients with substance use disorder. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, Baltimore, MD, May 19-23, 2018.

61. Dawwas G (g), Dietrich E, **Park H**. Effectiveness of apixaban versus warfarin for the prevention of cardiovascular diseases and recurrent venous thromboembolism. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19-23, 2018.
62. Garg M (g), Venugopalan V, Premraj S, **Park H**. Budget impact analysis of oritavancin for the treatment of moderate-to-severe acute bacterial skin and skin infections from a US hospital perspective. ISPOR 23rd Annual International Meeting, Baltimore, MD, May 19-23, 2018.
63. **Park H**, Wang W (g). Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. The Boston the Academy of Managed Care Pharmacy (AMCP), Boston, MA, April 23-26, 2018.
64. Boemmel-Wegmann B (g), **Park H**. Initiation rates, predictors, and cost burden of hepatitis C (HCV) treatment in HCV mono- vs HCV/HIV co-infected patients in the United States. The International Society for Pharmacoepidemiology (ISPE) Mid-Year Meeting, Toronto, Canada, April 21-24, 2018.
65. Dawwas G (g), **Park H**. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glp-1 in patients with type II diabetes. ISPE Mid-Year Meeting, Toronto, Canada, April 21-24, 2018.
66. Premraj G, Garg M (g), **Park H**, Cherabuddi K, Klinker K, Borgert S, Venugopalan V. Use of a severity assessment system in evaluating management of ssitis and identifying cost-minimization strategies at a large academic hospital. The 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Madrid, April 21-24, 2018.
67. Zou B, Yeo YH, Jeong D, Henry L, **Park H**, Nguyen MH. Cirrhotic patients with acute respiratory illness in the United States encounter substantial hospital charge burden. The American Association for the Study of Liver Disease (AASLD) of Liver Meeting, Washington DC, Oct 21-23, 2017. Hepatology 2017; 66: 408A-408A.
68. **Park H**, Jeong D, Nguyen P, Kim Y, Nguyen MH. Association of different types of chronic liver diseases with hepatocellular carcinoma in the United States. AASLD Liver Meeting Washington DC, Oct 21-23, 2017. Hepatology 2017; 66: 541A-542A.
69. Dave C (g), Park H., Winterstein A, Hartzema A, Longitudinal determinants of dynamic statin adherence: a retrospective cohort study. ISPOR 22nd Annual International Meeting. Boston, MA, May 20-24, 2017.
70. Dawwas G (g), **Park H**. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas in patients with type II diabetes. ISPOR 22nd Annual International meeting, Boston, MA, May 20-24, 2017.
71. Dave C (g), Park, H., Winterstein AI, Hartzema A., Performance of machine learning algorithms in predicting 30-day heart failure readmissions risk using an administrative claims database. ISPOR 22nd Annual International Meeting. Boston, MA. May 20-24, 2017.

72. Wang W (g), **Park, H.** Hepatitis C treatment in patients with hepatitis B virus/hepatitis C virus co-infection. ISPOR 22nd Annual International Meeting. Boston, MA. May 20-24, 2017. *Research Presentation Finalist Award.
73. **Park H.** Xinyue L (p), Liu W. Impact of FDA safety warnings on erythropoiesis stimulating agents prescribing among non-dialysis chronic kidney disease patients. ISPOR 22nd Annual International Meeting. Boston, MA. May 20-24, 2017.
74. Nguyen AL, Nguyen P, Jeong D, Hoang J, Sheen E, Kim YA, **Park H**, Nguyen MH. Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcohol related liver disease in the United States between 2005 and 2013. DDW, May 6-9, Chicago, IL, Gastroenterology 2017;152(5): S1200 – S1201.
75. **Park H.** Wang W (g), Chen C (g), Nelson DR. Chronic hepatitis C virus infection increases risk of cardiovascular disease and chronic kidney disease in the United States. AASLD Liver Meeting, Boston, Nov 11-15, 2016. Hepatology 2016; 64: 366A-487A.
76. Wang W (g), **Park H.** Association of interferon-based therapy and cardiovascular disease in chronic hepatitis C patients in the United States. ISPOR 21st Annual International Meeting, Washington DC. May 21-25, 2016.
77. Dawwas G (g), **Park H.** Impact of work and activity limitations attributable to arthritis on health-related quality of life in United States veterans. ISPOR 21st Annual International Meeting, Washington DC. May 21-25, 2016.
78. **Park H.** Adeyemi A (p), Roane T. The impact of a telephonic outreach program on medication adherence in Medicare Advantage Prescription Drug Plan members. ISPOR 18th Annual European Congress, Milan, Italy, Nov 2015. Value in Health 11/2015;18(7):A611 *Awarded the 2015 ISPOR Best New Investigator presentation award.
79. Adeyemi A (p), Roane T, **Park H.** The impact of a telephonic outreach program on medication adherence in Medicare Advantage Prescription Drug Plan members. AMCP Educational Conference, Orlando, FL, Oct 2015. *Awarded GOLD medal poster.
80. Younossi Z, **Park H**, Dieterich D, Saab S, Aijaz A, Gordon S. Quality-adjusted cost of care for treatment naïve (TN) patients with genotype 1 (GT1) chronic hepatitis C (CH-C): an assessment of innovation cost of drug regimens versus the value of health gains to society. AASLD Liver Meeting, San Francisco, CA, Nov 2015.
81. Younossi Z, **Park H**, Dieterich D, Saab S, Aijaz A, Gordon S. The value of cure associated with treating treatment-naïve (TN) chronic hepatitis C (CH-C) genotype 1 (GT1): are the new all oral regimes a good value to society? AASLD Liver Meeting, San Francisco, CA, Nov 2015.
82. **Park H**, Adeyemi A (p), Stepanova M, Linda H, Younossi Z. Hepatitis C virus (HCV) related arthritis and arthralgia: the epidemiologic and economic burden in the United States. The American College of Gastroenterology (ACG), Las Vegas, NV, Oct 2015.

83. Henry L, **Park H**, Adeyemi A (p), Stepanova M, Younossi Z. Depression and chronic hepatitis C (CHC): a common and costly association. ACG, Las Vegas, NV, Oct 2015.
84. Wang W (g), **Park H**. Risk factors associated with hospital admissions through Emergency Department among pediatric asthma. 30th ICPE, Boston, MA, Aug 2015.
85. **Park H**, Adeyemi A (p), Henry L, Stepanova M, Younossi Z. Association of Hepatitis C virus infection with risk of chronic kidney disease: systematic review and meta-analysis. ISPOR 19th Annual International Meeting, Philadelphia, PA, May 2015. Value in Health 2015;18(3):A223.
86. Wang W (g), **Park H**. Comparison on pediatric asthma hospital admissions through emergency department: Medicaid vs private insurance. ISPOR 19th Annual International Meeting, Philadelphia, PA, May 2015. Value in Health 2015;18(3):A171.
87. Kim YA, Raja P, DiCarlo L, Viridi N, **Park H**. An economic model of the impact of digital medicines with a mobile application in patients with comorbid hypertension, diabetes, and hypercholesterolemia. ISPOR 19th Annual International Meeting, Philadelphia, PA, May 2015. Value in Health;18(3):A40.
88. **Park H**, Aijaz A, Dieterich D, Saab S, Gordon S, Younossi Z. Projection of health outcomes comparing LDV/SOF vs. SOF+SMV – An analysis based on clinical trial vs. real-world data. DDW, Washington DC, May 2015. Gastroenterology 04/2015; 148(4): S970.
89. Younossi Z, **Park H**, Adeyemi A, Stepanova M, Henry L. Patient reported outcomes (PROs) in chronic hepatitis C (CHC): A meta-analysis of health related quality of life (HRQL) and fatigue data. DDW, Washington DC, May 2015. Gastroenterology 04/2015; 148(4): S503.
90. Younossi Z, **Park H**, Adeyemi A, Stepanova M, Henry L. A meta-analytic estimation of the burden of extra hepatic manifestations of hepatitis C. DDW, Washington DC, May 2015. Gastroenterology 04/2015; 148(4): S503.
91. Younossi Z, Stepanova M, Henry L, Nader F, **Park H**, Lam B, Pham H, Hunt S. The quality of life journey for patients with chronic hepatitis c: from interferon and ribavirin to interferon-free and ribavirin-free regimens. EASL, Vienna, Austria, April 2015. Journal of Hepatology 04/2015;62:S637.
92. Younossi Z, Stepanova M, Henry L, **Park H**, Racila A, Hunt S. Direct medical costs associated with the extrahepatic manifestations of hepatitis c infection in the United States. EASL, Vienna, Austria, April 2015. Journal of Hepatology 04/2015;62:S596.
93. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. The impact of Medicare Part D coverage on health outcomes in end-stage renal disease (ESRD) patients. The American Pharmacists Association (APhA) Annual Meeting & Exposition 2014, Orlando, FL, Mar 2014. *Awarded 2014 APhA-APRS Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences.
94. Younossi Z, Gordon S, Saab S, Ahmed A, **Park H**, Sulkowski M. Health and economic outcomes of Sofosbuvir therapy as predicted by a Markov model in the HCV/HIV co-infected population. ISPOR 18th Annual International Meeting, Montreal, Canada, Jun 2014. Value in Health 05/2014;17(3):A37. *Received post finalist award.

95. Saab S, Gordon S, **Park H**, Ahmed A, Younossi Z. A decision analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients and those without treatment options with chronic hepatitis C virus. DDW, Chicago, IL, May 2014. *Gastroenterology* 05/2014;146(5):S912.
96. Saab S, Gordon S, **Park H**, Aijaz A, Younossi Z. A decision analytic Markov model to evaluate the health outcomes of sofosbuvir for treatment-naïve and treatment-experienced patients with chronic hepatitis C virus genotype 3 infection. EASL, London, UK, Apr 2014. *Gastroenterology* 05/2014;146(5):S912.
97. **Park H**, Rascati KL, Keith MS. Examination of the budget impact of the bundled Medicare prospective payment system on dialysis organizations. The National Kidney Foundation (NKF) Clinical Meetings, Orlando, FL, Apr 2013.
98. **Park H**, Rascati KL, Keith MS. Budget impact model of Medicare bundled end-stage renal disease prospective payment system: A dialysis organization perspective. The American Society of Nephrology (ASN), San Diego, CA, Nov 2012.
99. **Park H**, Park C, Kim YA, Rascati KL. A meta-analysis of efficacy and safety of dipeptidyl-peptidase 4 [DPP4] inhibitors in type 2 diabetes. ISPOR 17th Annual International Meeting, Washington DC, Jun 2012. *Value in Health* 06/2012;15(4):A172.
100. **Park H**, Rascati KL. Direct costs of pneumonia in the U.S.: An analysis of 2007-2008 Medical Expenditure Panel Survey (MEPS) data. ISPOR 14th European Congress, Madrid, Spain, Nov 2011.
101. Rascati M, **Park H**, Rascati KL. Direct costs of head and neck cancer in the U.S.: An analysis of 2007-2008 Medical Expenditure Panel Survey (MEPS) data. ISPOR 14th European Congress, Madrid, Spain, Nov 2011.
102. Rascati KL, Prasla K, **Park H**, McBayne T. Evaluation of healthcare costs for patients with gout by serum uric acid. American College of Rheumatology 75th Annual Scientific Meeting, Chicago, IL, Nov 2011.
103. Kim D, **Park H**, Rascati K. Measures of medication adherence in orals vs. long-acting risperidone in Texas Medicaid patients with schizophrenia. ISPOR 16th Annual International Meeting, Baltimore, MD, May 2011. *Awarded 2011 ISPOR Best Poster Award.
104. Rascati KL, **Park H**, Prasla K, McBayne T. Comparison of healthcare costs for gout patients by uric acid level. AMCP 23rd Annual meeting, Minneapolis, MN, Apr 2011.
105. **Park H**, Kim D, Rascati KL. Comparisons of mental health-related medical care utilization and costs following the initiation of oral vs. long-acting injectable risperidone in patients with schizophrenia. ISPOR 16th Annual International Meeting, Baltimore, MD, May 2011.
106. Kim D, **Park H**, Rascati KL. Measures of medication adherence in orals vs. long-acting risperidone in Texas Medicaid patients with schizophrenia. The Western Pharmacoeconomics Conference 2011, Seattle, WA, Mar 2011.

107. **Park H**, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl-peptidase 4 [DPP4] inhibitors in type 2 diabetes: Meta-analysis. APhA Annual Meeting & Exposition 2011, Seattle, WA, Mar 2011. *Awarded 2011 APhA-APRS Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences.
108. Patel P, Shah M, D'Souza A, **Park H**. Economic impact of using a hand-carried ultrasound for diagnostic thoracentesis in patients with parapneumonic effusions. 40th Critical Care Congress, San Diego, CA, Jan 2011.
109. **Park H**, Rascati KL, Keith MS. Cost-effectiveness of lanthanum vs. sevelamer hydrochloride for the treatment of hyperphosphatemia in dialysis patients. ASN, Denver, CO, Nov 2010.
110. **Park H**, Rascati KL, Keith MS. The cost-effectiveness of lanthanum carbonate vs. sevelamer hydrochloride in patients with end-stage renal disease. ISPOR 13th European Congress, Prague, Czech Republic, Nov 2010.
111. **Park H**, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl-peptidase 4 [DPP4] inhibitors in type 2 diabetes: Meta-analysis. ISPOR 13th European Congress, Prague, Czech Republic, Nov 2010.
112. **Park H**, Rascati KL, Keith MS, et al. The value of lanthanum carbonate vs. sevelamer hydrochloride in end-stage renal disease patients: An economic evaluation from a US payer perspective. AMCP Educational Conference, St. Louis, MO, Oct 2010.

PODIUM PRESENTATIONS (peer-reviewed; reverse chronological order; underline denotes corresponding author; g denotes student; p denotes postdoc)

1. Unigwe IF (g), Goodin A, Lo-Ciganic WH, Cook RL, Wilson DL, **Park H**. Pre-exposure prophylaxis adherence trajectories and HIV and sexually transmitted infections risk. ISPOR, 2024; May 5 – 8, Atlanta, Georgia, USA. [submitted].
2. Huang PL, Chang SH(g), Cabrera R, Wilson DL, **Park H**. Effects of direct-acting antivirals on end-stage liver disease and mortality among Florida Medicaid beneficiaries with chronic hepatitis C. EASL Congress, 2024; June 5 – 8, Milan, Italy. [submitted].
3. Kaufmann CN, Riaz M(g), **Park H**, Lo-Ciganic J, Wilson D, Malhotra A, Wickwire EM, Bhattacharjee R. Evidence for an Independent Association of Cardiovascular Disease in Patients with Narcolepsy. Associated Professional Sleep Societies' (APSS) Sleep 2024; June 1 – 5, 2024, Houston, TX. [submitted].
4. Riaz M(g), Kaufmann CN, Bhattacharjee R, Lo-Ciganic J, Wilson D, Malhotra A, Wickwire EM, **Park H**. Association between Narcolepsy and Cardiovascular Outcomes: A Comprehensive Analysis Controlling for Medication Use. Associated Professional Sleep Societies' (APSS) Sleep 2024; June 1 – 5, 2024, Houston, TX. [submitted].
5. Hernandez-Con, P., Park, H., Maguire, M., Keshwani, S. and Hincapie-Castillo, J. Prescription patterns in patients with incident trigeminal neuralgia. *Pharmacoepidemiol Drug Saf.* 2022;31, pp. 403-403. (Podium presentation at the 2022 38th ICPE, August 24-28, 2022)

6. **Park H**, Kang H, Huang P, Lo-Ciganic W, Dietrich E, Murphy M, DeRemer C. Comparative Effectiveness and Safety of Extended Anticoagulant Therapy Among Medicare Beneficiaries with Venous Thromboembolism. *Blood* 2021; 138 (Supplement 1): 178. 63rd American Society of Hematology, Atlanta, GA. Dec 2021.
7. Song H, Jiang X, Chang CY, Wilson D, Lo-Ciganic W, **Park H**. Effects of Direct-acting antivirals for hepatitis C virus on hepatocellular carcinoma and mortality among Medicaid beneficiaries. Digestive Disease Week 2022, San Diego, CA, May 2022
8. Goodin A, Huang J, **Park H**, Skvarla D, Hincapie-Castillo JM, Lo-Ciganic W. Controlled Substance Prescription Utilization Trends in Arizona from 2011-2016, by Prescription Class. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. *Subst Abus.* 2019;40(4):469-472 (Supp 113). 2019 Addiction Health Services Research Conference, Park City, UT.
9. Goodin A, Huang J, **Park H**, Hincapie-Castillo J, Brown J, Costales B, Lo-Ciganic W. Change in Buprenorphine Prescriptions for Opioid Use Disorder Indications in Arizona from 2011-2016. 2019 Addiction Health Services Research (AHSR), Salt Lake City, Utah, USA, October 16-18, 2019.
10. Wang W (g), Lo Re III V, Guo Y, Xiao H, Brown J, **Park H**. The increased risks of non-hepatic cancers among hepatitis c virus (HCV) infected patients: a population-based cohort study in the U.S. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
11. Wang W (g), Lo Re III V, Guo Y, Xiao H, Brown J, **Park H**. The clinical and economic impact of hcv treatment on non-hepatic cancers among HCV-infected patients. ISPOR 24rd Annual International Meeting, New Orleans, LA, May 18-22, 2019.
12. **Park H**, Wang W (g), Henry L. Nelson D. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. The American Association for the Study of Liver Disease (AASLD) of Liver Meeting, San Francisco, CA, November 9-13, 2018. *Hepatology* 2018;68(S1).
13. Dawwas G (g), **Park H**. Effectiveness of Apixaban versus Rivaroxaban for the Prevention of Cardiovascular Diseases and Recurrent Venous Thromboembolism. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Prague, Czech Republic, August 22-26.
14. Dawwas G (g), Dietrich E, Winchester D, Winterstein A, Segal R, **Park H**. Comparative Effectiveness of Prasugrel versus Ticagrelor for the Prevention of Cardiovascular Diseases in Patients with Acute Coronary Syndrome. 34th ICPE, Prague, Czech Republic, August 22-26, 2018.
15. Wang W (g), Lo Re III, Xiao H, Guo Y, **Park H**. Incidence of hepatocellular carcinoma and extrahepatic cancers among HCV patients in the era of direct-acting antivirals. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, Baltimore, Maryland, May 19-23, 2018.

16. Dawwas G (g), **Park H**. Cardiovascular Safety of Sodium Glucose Cotransporter-2 Inhibitors versus Sulfonylureas in Patients with Type II Diabetes Mellitus. 33rd ICPE, Montreal, Canada, August 26-30, 2017. Pharmacoeconomics Drug Safety 2017;26 (S2).
17. Choi Y (g), Meissner C, **Park H**, Brumback B, Winterstein A. Determine of days since last active medical support for chronic lung disease, associated respiratory syncytial virus hospitalizations in infants. 33rd ICPE, Montreal, Canada, August 26-30, 2017. Pharmacoeconomics Drug Safety 2017;26 (S2).
18. Jiang X (g), **Park H**, Xiao H, Segal R. Trends in readmission rate and hospital charge for patients with chronic obstructive pulmonary disease in Florida from 2009 to 2014. ISPOR 22nd Annual International Meeting, Boston, MA, May 20-24, 2017.
19. Choi Y (g), Meissner C, Hampp C, **Park H**, Brumback B, Winterstein A. Development of a predictive model for respiratory syncytial virus hospitalizations among infants. International Society for Pharmacoeconomics (ISPE) Mid-Year Meeting, April 1-4, 2017, London, U.K. *Selected as one of top twelve award winning abstracts
20. **Park, H**, Jeong, D, Nguyen, P, Hoang, J, Kim, Y, Sheen, E, Nguyen, M, The Increasing Burden of Hospital Charges from Viral Hepatitis in the United States. The Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2017, Shanghai, China. Feb 17, 2017.
21. Dawwas G (g), **Park H**. Changes in diabetes therapy one year before and after discharge from a heart failure hospitalization among patients with type II diabetes. 32th ICPE, Dublin, Ireland, Aug 24- 28, 2016.
22. Boemmel-Wegmann S (g), **Park H**. Influenza vaccination update among adult asthma patients in the United States. 32th ICPE, Dublin, Ireland, Aug 24- 28, 2016.
23. Chen C (g), Wang W (g), Cook RL, **Park H**. Hepatitis C virus infection increases risk of developing chronic kidney disease. 32th ICPE, Dublin, Ireland, Aug 24- 28, 2016. Pharmacoeconomics and Drug Safety. 2016; 25: 470-471.
24. Dave C (g), Hartzema A, **Park H**, Winterstein A. Baseline and time-varying determinants of statin adherence. 32nd ICPE, Dublin, Ireland, Aug 24- 28, 2016.
25. Aijaz A, Dieterich D, **Park H**, Saab S, Gordon S, Younossi Z. A Cost-Effectiveness Analysis of LDV/SOF+RBV for 12 weeks vs. LDV/SOF 24 Weeks vs. SOF+SMV 24 Weeks in CHC GT1 TE Cirrhotic Patients. The Digestive Disease Week (DDW), Washington DC, May 2015.
26. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. The Impact of Medicare Part D Coverage on Medication Adherence and Health Outcomes in End-Stage Renal Disease (ESRD) Patients. The Western Pharmacoeconomics Conference (WPC), Tucson, AZ, Mar 2013. *Awarded WPC Best Podium Award.
27. **Park H**, Rascati KL, Lawson KA, Barner JC, Richards KE, Malone DC. The Impact of Medicare Part D Coverage on Medication Adherence and Health Outcomes in End-

Stage Renal Disease (ESRD) Patients. ISPOR 18th Annual International Meeting, New Orleans, LA, May 2013. Value in Health 05/2013;16(3):A10.

28. **Park H**, Rascati KL, Keith MS. Estimating the budget impact of the Medicare bundled end-stage renal disease prospective payment system from a dialysis organization perspective. The Annual Dialysis Conference (ADC), Seattle, WA, Mar 2013.
29. **Park H**, Kim D, Rascati KL. Healthcare costs associated with initiating oral vs. long-acting injectable risperidone in patients with schizophrenia. The American Pharmacists Association (APhA) Annual Meeting & Exposition 2012, New Orleans, LA, Mar 2012.
30. **Park H**, Kim D, Rascati KL. Comparisons of mental health-related medical care utilization and costs following the initiation of oral vs. long-acting injectable risperidone in patients with schizophrenia. WPC, Seattle, WA, Mar 2011.

INVITED PRESENTATIONS (reverse chronological order; underline denotes corresponding author; g denotes student; p denotes postdoc)

1. **Park H**. Fundamentals of Pharmacoeconomics. American Society for Clinical Pharmacology & Therapeutics (ASCPT) Webinar; January 16, 2024; Virtual
2. **Park H**. Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool. Presented at: Southern HIV and Alcohol Research Consortium (SHARC) Community Advisory Board Meeting; November 15, 2023; Gainesville, FL.
3. **Park H**. Disparities in Access to Hepatitis C Treatment/Hepatitis C Treatment Outcomes. Presented at: Hep Free AZ Meeting; Arizona Department of Health Services; July 19, 2023; Virtual.
4. **Park H**. Effects of Direct Acting Antivirals for Chronic Hepatitis C virus. University of Texas at Austin, Austin, TX; April 2019; Austin, TX.
5. **Park H**. Cost-effectiveness of sofosbuvir in the treatment of chronic Hepatitis C virus genotype 1 infection; University of Texas ISPOR student chapter; September 29, 2014; Austin, TX.

TEACHING

University of Florida, College of Pharmacy (2013 – present)

Critical Appraisal of Pharmacoeconomic Studies (PHA5267); 3rd year PharmD students Spring semester (1 credit hour). Approximately 280 students; Course coordinator and lectured 100% (2014-2017). This 8-week course in legacy curriculum introduces students to fundamental methods of pharmacoeconomic analysis and enhance students' ability to apply knowledge of pharmacoeconomic

Principles of Pharmacoeconomics (PHA5933); 2nd year PharmD students Fall semester (1 credit hour). Approximately 250 students; Course coordinator and lectured 95% (2016-present). This 2-week course consists of 2 team-based learning sessions, 7 content modules, and online quiz to provide a number of opportunities to critique current literature and apply pharmacoeconomic principles through relevant practice exercises and team-based activities.

Introduction to Pharmaceutical Outcomes & Policy (PHA6265/6266); 1-2nd year graduate students in POP department Spring semester (3 credit hours). Approximately 5-10 students. Instructor and lectured 15% (2014-present). I have developed three research modules including an introduction to research in health policy, meta-analysis, and medication adherence. Each module summarizes the research topics, its strength and challenges, and discussed study methods and issues.

Patient Care IV Gastrointestinal and Renal Disorders (PHA5784C); 3rd year PharmD students for meta-analysis transcending module and active learning session.

Patient Care VI Skin and Musculoskeletal Disorders (PHA5788C); 3rd year PharmD students for budget impact model transcending module.

Pharmaceutical Outcomes and Policy department research Seminar (PHA6279); All graduate students in POP department. Fall and Spring semester (2 credit hours). Course coordinator (2017-2018). I coordinated seminar and introduced a writing skills component.

An Introduction to Drug Discovery and Development (PHA6935); 1st - 2nd year college of pharmacy graduate students; summer 2017 (1 credit hour). Lecturer for pharmacoeconomics.

University of Texas at Austin, College of Pharmacy (2011- 2013)

Advanced Research Methods (PHR 281M); 4-5th year graduate students (3 credit hours) Instructor for advanced pharmacoeconomics (2011 & 2013)

ADVISING and MENTORSHIP

Primary Graduate Trainee Advisor/Mentor

<u>Name</u>	<u>Date</u>	<u>Degree</u>	<u>Current Status</u>
Ghadeer Dawwas	2013-2018	MS, PhD	Completed - U Penn
Wei Wang	2013-2018	PhD	Completed - Merck & Co.
Sascha Wegmann	2014-2019	MS, PhD	Completed - Bayer AG
Xinyi Jiang	2014-2020	MS, PhD	Completed - CDC
Mahek Garg	2016-2021	PhD	Completed - Merck & Co.
Raj Desai (Co-Chair)	2018-2022	PhD	Completed - Analysis group
Munaza Riaz	2018-2023	PhD	Completed - U of Florida
Ikenna Unigwe	2019-present	PhD	Completed - Boehringer Ingelheim
Pilar Hernandez	2020-present	PhD	Enrolled in program
Shao-Husan Chang	2021-present	MS, PhD	Enrolled in program

Dissertation Committee Member

<u>Name</u>	<u>Date</u>	<u>Degree</u>	<u>Primary advisor</u>
Nakyung Jeon	2012-2017	PhD	Almut Winterstein, PhD
Chiantan Dave	2012-2017	PhD	Bram Hartzma, PhD
Jevay Grooms	2014-2016 (external)	PhD	Jonathan Hamilton, PhD
Yoonyoung Choi	2013-2018	PhD	Almut Winterstein, PhD
Abdullah Alalwan	2013-2018	PhD	Bram Hartzma, PhD
Ching-Yu Wang	2018-2021	PhD	Joshua Brown, PhD
Ziyan Chen	2017-2021	PhD	Vakaramoko Diaby, PhD
Patrick Squires	2017-2021	PhD	Joshua Brown, PhD

Aima Okpeku	2019-2021	MS	Amie Goodin, PhD
Ching-Yuan Chang	2019-2022	PhD	Jenny Lo-Ciganic, PhD
Seonkyeong Yang	2019-present	PhD	Jenny Lo-Ciganic, PhD
Shailina Keshwani	2020-present	PhD	Steve Smith, PharmD
Asinamai Ndai	2020-present	PhD	Steve Smith, PharmD
Kayla Smith	2022-present	PhD	Steve Smith, PharmD
Hung-Kai Chen	2023-present	PhD	Almut Winterstein, PhD

Post-doc Associate Advisor

<u>Name</u>	<u>Date</u>	<u>Current Status</u>
Ayo Adeyemi, PhD	2014-2015	Biogen
Sarah Liu, PhD	2016-2018	Merck & Co.
Ghadeer Dawwas, PhD	2019	U Penn
Hyunjin Song, PhD	2018-2022	
Hyerim Kang, PhD	2020-2022	Sanofi-Aventis
Munaza Riaz	2023-present	

Research Supervisor

<u>Name</u>	<u>Date</u>	<u>Degree</u>	<u>Project</u>
Ashley Stultz	2022-present	PharmD	HIV Pre-exposure prophylaxis (PrEP) Care Continuum in the Emergency Room and Outpatient Setting: A Systematic Review with Meta-Analysis
Natalie Ourhann	2020-2022	PharmD	The care cascade of hepatitis C virus in the direct-acting antiviral era: A systematic review and meta-analysis

SCHOLARSHIPS AND AWARDS

May 23	UF College of Pharmacy Outstanding Publication in Clinical Science Research Award
May 22	UF College of Pharmacy Best Dissertation Mentoring Award
May 19	UF College of Pharmacy Outstanding Publication in Clinical Science Research Award
Nov 18	AASLD-EASL Masterclass, Orlando, Florida
Nov 15	Best Poster Award at the Academy Managed Care Pharmacy (AMCP) Annual Conference
Nov 15	Best New Investigator Presentation Award at the ISPOR 18 th Annual European Congress, Milan, Italy
Apr 15	Excellence Award for Assistant Professor, University of Florida
Mar 14	Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences (ESAS) at the APhA 2014 Annual Meeting, Orlando, FL
Mar 13	Best Podium Award at the Western Pharmacoeconomic Conference (WPC), Tucson, AZ
Sep 12 – May 13	The University of Texas Continuing Fellowship Award
Jun 12	1 st place for ISPOR Outstanding Student Chapter Award at the ISPOR 17 th Annual International Meeting, Washington DC
Jun 12	ISPOR Distinguished Service Award at the ISPOR 17 th Annual International Meeting, Washington DC
Sep 11 – Aug 12	The University of Texas Continuing Fellowship Award
May 11	Best Poster Award at the ISPOR 16 th Annual International Meeting, Baltimore, MD

Mar 11 Postgraduate Best Paper Award in the Economic, Social & Administrative Sciences (ESAS) at the APhA 2011 Annual Meeting, Seattle, WA

PROFESSIONAL ORGANIZATIONS

2008 – present International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
2009 – present International Society for Pharmacoepidemiology (ISPE)
2011 – present American Pharmacists Association (APhA)
2015 – present American Association for the Study of Liver Diseases (AASLD)

PROFESSIONAL SERVICE

2023 Peer Promotion and Tenure Packet External Reviewer, University of Tennessee
2021-present American Pharmacists Association (APhA) economic, social and administrative sciences (ESAS) Nominations and Awards Committee, Member and Reviewer
2021- 2022 Quality Metrics Expert Panel, Measurement development: Migraine, Pharmacy Quality Alliance (PQA)
2015 – present Faculty advisor, International Society for Pharmacoeconomics and Outcomes Research UF chapter

UNIVERSITY OF FLORIDA SERVICE (2013-present)

2023 Search Committee for Pharmaceutical Outcomes & Policy Department Chair, *Member*
2023 Peer Teaching Evaluations (n=2) College of Pharmacy, Reviewer
2022 Peer Teaching Evaluations (n=1) College of Pharmacy, Reviewer
2019 – present The Southern HIV and Alcohol Research Consortium (SHARC), UF Core Faculty Member
2019 – present College of Pharmacy Tenure & Promotion Committee, Member
2019 Search Committee for Asst/Assoc Prof, Pharmaceutical Outcomes & Policy, Chair
2018 – 2000 Faculty Development Committee, Member
2016 – present College of Pharmacy Research Committee, Member
2016 – 2020 Graduate Education Task Force Committee, Member
2015 Search Committee for Pharmaceutical Outcomes & Policy Department Chair, *Member*
2014 – present Search Committee for Asst/Assoc Prof, Pharmaceutical Outcomes & Policy, Member
2014 – 2018 Professionalism Committee, Member

PEER REVIEW ACTIVITIES

2023 – present Manuscript Reviewer, Lancet EClinical Medicine
2022 – present Manuscript Reviewer, Journal of the American College of Cardiology
2021 – present Manuscript Reviewer, The Lancet Gastroenterology & Hepatology
2018 – present Abstract Reviewer, Academy of Managed Care Pharmacy (AMCP)
2018 Podium Judge, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference
2018 – present Manuscript Reviewer, Journal of Hepatology
2018 – present Manuscript Reviewer, Diabetes, Obesity and Metabolism
2017 – present Manuscript Reviewer, Scientific Reports
2018 – present Manuscript Reviewer, Research in Social & Administrative Pharmacy

2016 – present	Manuscript Reviewer, Journal of the American Society of Nephrology
2016 – present	Manuscript Reviewer, Digestive Diseases and Sciences
2016 – present	Manuscript Reviewer, BMC Infectious Diseases
2015 – present	Manuscript Reviewer, American Journal of Kidney Disease
2015 – present	Manuscript Reviewer, Value in Health
2014 – present	Manuscript Reviewer, American Journal of Cardiovascular Drugs
2014 – present	Manuscript Reviewer, Annals of Pharmacotherapy
2013 – present	Manuscript Reviewer, American Journal of Managed Care
2013 – present	Manuscript Reviewer, Journal of Medical Economics
2013 – present	Manuscript Reviewer, Clinical Therapeutics

PROFESSIONAL LICENSURE

2000 – present	Registered Pharmacist in South Korea
----------------	--------------------------------------